Business
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y., January 21, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025.
About this update from Delcath Systems, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/4335d3c17cc55e47fbb79453a9b9fb6c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AigbhkQ5P29YeQZqRKcurA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4335d3c17cc55e47fbb79453a9b9fb6c","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QPl55I5YIJ273BQXr9EWsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/4335d3c17cc55e47fbb79453a9b9fb6c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"QUEENSBURY, N.Y., January 21, 2026--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025.","length":471,"tagName":"p"},{"type":"text","content":"The grants, in the form of Restricted Stock Units (RSUs), totaled 36,250 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan ("Plan"). The RSUs were granted on January 2, 2026 and one-third of the RSUs will vest on the first anniversary of the grant date with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The RSUs are subject to the employee’s continued employment with Delcath on each vesting date.","length":535,"tagName":"p"},{"type":"text","content":"The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.","length":136,"tagName":"p"},{"type":"text","content":"About Delcath Systems, Inc.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan pe...